Claimf499e71d4c923170a2f7848dd1dad9189ec83f6d45c852d6deb072a4c2349b7d·My Arguments

Claim

Mendelian randomization studies are being deployed to proxy longer-term exposure, but these estimate the effect of lifelong genetic variation in GLP-1 signaling rather than pharmacological exposure starting in mid-life, limiting their direct applicability to drug safety questions.

Evidence (1)

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy: A 2x2 Factorial Mendelian Randomization Study

Biobank-scale MR study attempting to address long-term questions RCTs cannot, but with inherent limitations of genetic proxy approach.

https://www.medrxiv.org/content/10.1101/2025.07.15.25331531.full.pdf

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/f499e71d4c923170a2f7848dd1dad9189ec83f6d45c852d6deb072a4c2349b7d"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberation Join & respond